Top line interim data on the eye drop clinical trial with age-related macular degeneration with my companys experimental Squalamine eye drop product with 60 patients who completed 9 months of daily eye drop treatment. Vision continued to improve over time. The blue bars show the vision enhancement of 3 lines, 4 lines and 5 line gainers on the ETDRS eye chart (5 letters a line) over the standard of care (red bars) Lucentis, by using the eye drops. Remarkable and substantial increases and recovery of vision that had been lost to the disease were observed over Lucentsi treatment. The results are looking very promising and we look forward to getting the results in the entire 120 patients enrolled in the trial early next year. We will present more detailed data on the trial results at an ophthalmology conference later this year.
Posted on: Mon, 30 Jun 2014 02:11:13 +0000
Trending Topics
Recently Viewed Topics
© 2015